Who is betting on what in AI, and against whom.
AlphaFold lineage, drug design.
Alphabet's drug-design company, spun out of DeepMind around AlphaFold. It took its first outside money, $600M led by Thrive Capital, in March 2025 to push programs into the clinic.
| Amount | Kind | Valuation | Date | Investors | Source |
|---|---|---|---|---|---|
| $600M | funding round | Mar 2025 | Thrive Capital, GV, Alphabet | TechCrunch |
No people recorded at this lab yet.